NRX Pharmaceuticals
NRXP
23 hedge funds and large institutions have $16.2M invested in NRX Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 8 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
28% more funds holding
Funds holding: 18 → 23 (+5)
0.02% less ownership
Funds ownership: 0.34% → 0.33% (-0.02%)
14% less capital invested
Capital invested by funds: $18.9M → $16.2M (-$2.71M)
51% less call options, than puts
Call options by funds: $3.24M | Put options by funds: $6.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.72M |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.76M |
| 4 |
Jane Street
New York
|
+$1M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$720K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
-$4.23M |
| 2 |
OCAM
Owl Creek Asset Management
New York
|
-$3.25M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$1.52M |
| 4 |
ICM
Ionic Capital Management
New York
|
-$415K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$139K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
26
Ionic Capital Management
New York
| – | -$415K | -3,572 | Closed |
|
|
YCM
27
Yakira Capital Management
Westport,
Connecticut
| – | -$139K | -1,192 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$97K | -839 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$93K | -800 | Closed |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -20 | Closed |
|
|
SFPG
31
Stonebridge Financial Planning Group
Orlando,
Florida
| – | -$1K | -8 | Closed |
|
NRXP Hedge Fund Activity: Q3 2021 in Review
23 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2021, worth a combined $16.2M — down 14% from $18.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NRXP positions and 8 closed out — a net gain of 6 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.72M. The largest seller was Linden Advisors, exiting entirely with an estimated $4.23M sold.
- 23 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2021, up from 18 in Q2 2021.
- Funds reported $16.2M of NRX Pharmaceuticals stock for Q3 2021, down 14% quarter-over-quarter.
- 14 funds opened new NRX Pharmaceuticals positions in Q3 2021 and 8 closed out, a net change of +6 holders.
- The largest NRX Pharmaceuticals buyer in Q3 2021 was Vanguard Group, an estimated $4.72M added.
- The largest NRX Pharmaceuticals seller in Q3 2021 was Linden Advisors, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2021.